Key facts
- Notable investors include Hangzhou Shenghui Jingchen Investment Management, Harmony Invest, Sunbow Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Infinory
- ·The full record, as it builds
Funding rounds
No funding rounds for Infinory are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Infinory
Developer of oncolytic virus-based biopharmaceutical technologies designed for first-in-class anticancer drug innovation. The company is built on engineered oncolytic adenoviruses supported by leading serum-free suspension manufacturing processes, validated antitumor activity, intravenous delivery capabilities, and expert-led R&D in virology and gene therapy, enabling oncology researchers and clinicians to advance multiple Class I innovative drug candidates including a Phase II oncolytic virus program with demonstrated efficacy accelerate clinical translation, expand therapeutic options, and prepare products for clinical grade production at globally competitive standards.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- in-finory.com/
- Ownership
- Privately Held (backing)
Infinory doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Infinory shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Infinory in its N-PORT filings yet. We sweep new filings monthly.